Dra. Cajigas, you were appointed Director General of INVIMA just over two years ago. What have been the biggest challenges that you have faced since the…
In Conversation
“ An expert in trade and regulatory issues relating to the pharmaceutical industry in Colombia, the senior partner of Espíndola International Consultants offers his opinions on the steps… ”
Mr. Egan, what path led you to IMS Health? My original background is in science—I received a PhD in medical microbiology, and worked for some time…
Can you please tell our readers, what were some of ALK’s highlights in 2012? We had several important milestones in 2012. We advanced our research and…
Why did MSD decide to have Denmark as the headquarters for the Mid Europe 2 region? This Mid Europe 2 region consists of 10 countries, most of…
After establishing the operations of ChemPartner in 2009, can you tell our readers why Denmark? ChemPartner is a leading contract research laboratory within drug discovery. When…
The last years have been challenging Sanofi since many of your historic blockbuster drugs that have driven the growth of Sanofi in the past, have faced…
Prior to working as General Manager of Sanofi Colombia, you worked in similar positions in Ecuador and Venezuela. What was your initial mission upon returning to…
When we interviewed you in 2010, there were 182 pharmaceutical companies in Colombia, representing 2.5 percent of total Colombian manufacturing output (surpassing traditional industries such as…
Prior to Hospira, you worked for a number of years in several positions at Bayer. What opportunities did you see in moving your career from Bayer…
“ Pharmaceutical Executive ”
Can you please introduce yourself, and Ernst & Young’s life science practice in Ireland, to our readers? I am the managing partner of Ernst & Young…
